-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, March 5, on March 3, the official website of the State Food and Drug Administration showed that Chengdu Xinjie High-tech/Sichuan Meida Kangjiale Pharmaceutical's 3 generic drug bromhexine hydrochloride injection was approved for production and deemed to have been produced.
Comment, it is the first in China.
According to data from Meinenet, the sales of terminal bromhexine hydrochloride injections in China's public medical institutions exceeded 2 billion yuan in 2019.
Comment, it is the first in China.
According to data from Meinenet, the sales of terminal bromhexine hydrochloride injections in China's public medical institutions exceeded 2 billion yuan in 2019.
Source: official website of the State Food and Drug Administration
Bromhexine hydrochloride is a mucolytic expectorant.
It can not only dissolve mucous sputum, but also reduce the viscosity of sputum, make sputum easy to cough up, and keep the airway unobstructed.
It is mainly used clinically for bronchitis, asthma, Emphysema and other sticky phlegm are not easy to cough up.
It can not only dissolve mucous sputum, but also reduce the viscosity of sputum, make sputum easy to cough up, and keep the airway unobstructed.
It is mainly used clinically for bronchitis, asthma, Emphysema and other sticky phlegm are not easy to cough up.
At present, the main dosage forms of bromhexine hydrochloride marketed in China are injections and tablets.
Among them, injections (including bromhexine hydrochloride glucose injection, bromhexine hydrochloride for injection, and bromhexine hydrochloride injection) are widely used.
Among them, injections (including bromhexine hydrochloride glucose injection, bromhexine hydrochloride for injection, and bromhexine hydrochloride injection) are widely used.
According to data from Menet.
com, in 2019, the sales of terminal bromhexine hydrochloride injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) exceeded 2 billion yuan, and the growth rate in the first half of 2020 will be higher.
The decline.
From the perspective of the competitive landscape of manufacturers, Kelun dominates the market with a market share of more than 20%.
com, in 2019, the sales of terminal bromhexine hydrochloride injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) exceeded 2 billion yuan, and the growth rate in the first half of 2020 will be higher.
The decline.
From the perspective of the competitive landscape of manufacturers, Kelun dominates the market with a market share of more than 20%.
Consistency evaluation of bromhexine hydrochloride injection
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
2 companies submitted supplementary applications for the consistency evaluation of bromhexine hydrochloride injection, which are still under review and approval; 4 companies submitted applications for the listing of this product in imitation category 3, among which Chengdu Xinjie High-tech Development/Sichuan Meida Kangjiale Pharmaceutical products have been approved for production and deemed to have been reviewed, making it the first domestic company.
Source: Mi Neiwang database, State Food and Drug Administration
Note: The statistics are as of March 3, if there are any omissions, please correct me!
Medical Network News, March 5, on March 3, the official website of the State Food and Drug Administration showed that Chengdu Xinjie High-tech/Sichuan Meida Kangjiale Pharmaceutical's 3 generic drug bromhexine hydrochloride injection was approved for production and deemed to have been produced.
Comment, it is the first in China.
According to data from Meinenet, the sales of terminal bromhexine hydrochloride injections in China's public medical institutions exceeded 2 billion yuan in 2019.
Comment, it is the first in China.
According to data from Meinenet, the sales of terminal bromhexine hydrochloride injections in China's public medical institutions exceeded 2 billion yuan in 2019.
Source: official website of the State Food and Drug Administration
Bromhexine hydrochloride is a mucolytic expectorant.
It can not only dissolve mucous sputum, but also reduce the viscosity of sputum, make sputum easy to cough up, and keep the airway unobstructed.
It is mainly used clinically for bronchitis, asthma, Emphysema and other sticky phlegm are not easy to cough up.
It can not only dissolve mucous sputum, but also reduce the viscosity of sputum, make sputum easy to cough up, and keep the airway unobstructed.
It is mainly used clinically for bronchitis, asthma, Emphysema and other sticky phlegm are not easy to cough up.
At present, the main dosage forms of bromhexine hydrochloride marketed in China are injections and tablets.
Among them, injections (including bromhexine hydrochloride glucose injection, bromhexine hydrochloride for injection, and bromhexine hydrochloride injection) are widely used.
Among them, injections (including bromhexine hydrochloride glucose injection, bromhexine hydrochloride for injection, and bromhexine hydrochloride injection) are widely used.
According to data from Menet.
com, in 2019, the sales of terminal bromhexine hydrochloride injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) exceeded 2 billion yuan, and the growth rate in the first half of 2020 will be higher.
The decline.
From the perspective of the competitive landscape of manufacturers, Kelun dominates the market with a market share of more than 20%.
com, in 2019, the sales of terminal bromhexine hydrochloride injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) exceeded 2 billion yuan, and the growth rate in the first half of 2020 will be higher.
The decline.
From the perspective of the competitive landscape of manufacturers, Kelun dominates the market with a market share of more than 20%.
Consistency evaluation of bromhexine hydrochloride injection
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
2 companies submitted supplementary applications for the consistency evaluation of bromhexine hydrochloride injection, which are still under review and approval; 4 companies submitted applications for the listing of this product in imitation category 3, among which Chengdu Xinjie High-tech Development/Sichuan Meida Kangjiale Pharmaceutical products have been approved for production and deemed to have been reviewed, making it the first domestic company.
Source: Mi Neiwang database, State Food and Drug Administration
Note: The statistics are as of March 3, if there are any omissions, please correct me!
Medical Network News, March 5, on March 3, the official website of the State Food and Drug Administration showed that Chengdu Xinjie High-tech/Sichuan Meida Kangjiale Pharmaceutical's 3 generic drug bromhexine hydrochloride injection was approved for production and deemed to have been produced.
Comment, it is the first in China.
According to data from Meinenet, the sales of terminal bromhexine hydrochloride injections in China's public medical institutions exceeded 2 billion yuan in 2019.
Comment, it is the first in China.
According to data from Meinenet, the sales of terminal bromhexine hydrochloride injections in China's public medical institutions exceeded 2 billion yuan in 2019.
Source: official website of the State Food and Drug Administration
Bromhexine hydrochloride is a mucolytic expectorant.
It can not only dissolve mucous sputum, but also reduce the viscosity of sputum, make sputum easy to cough up, and keep the airway unobstructed.
It is mainly used clinically for bronchitis, asthma, Emphysema and other sticky phlegm are not easy to cough up.
It can not only dissolve mucous sputum, but also reduce the viscosity of sputum, make sputum easy to cough up, and keep the airway unobstructed.
It is mainly used clinically for bronchitis, asthma, Emphysema and other sticky phlegm are not easy to cough up.
At present, the main dosage forms of bromhexine hydrochloride marketed in China are injections and tablets.
Among them, injections (including bromhexine hydrochloride glucose injection, bromhexine hydrochloride for injection, and bromhexine hydrochloride injection) are widely used.
Among them, injections (including bromhexine hydrochloride glucose injection, bromhexine hydrochloride for injection, and bromhexine hydrochloride injection) are widely used.
According to data from Menet.
com, in 2019, the sales of terminal bromhexine hydrochloride injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) exceeded 2 billion yuan, and the growth rate in the first half of 2020 will be higher.
The decline.
From the perspective of the competitive landscape of manufacturers, Kelun dominates the market with a market share of more than 20%.
Hospital hospital hospitalcom, in 2019, the sales of terminal bromhexine hydrochloride injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) exceeded 2 billion yuan, and the growth rate in the first half of 2020 will be higher.
The decline.
From the perspective of the competitive landscape of manufacturers, Kelun dominates the market with a market share of more than 20%.
Consistency evaluation of bromhexine hydrochloride injection
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
2 companies submitted supplementary applications for the consistency evaluation of bromhexine hydrochloride injection, which are still under review and approval; 4 companies submitted applications for the listing of this product in imitation category 3, among which Chengdu Xinjie High-tech Development/Sichuan Meida Kangjiale Pharmaceutical products have been approved for production and deemed to have been reviewed, making it the first domestic company.
Enterprise business enterprise Source: Mi Neiwang database, State Food and Drug Administration
Note: The statistics are as of March 3, if there are any omissions, please correct me!
